Checkpoint Therapeutics Inc (CKPT) Stock Price, Quote & News

Company Profile

Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignanci...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Fax: 646 619 4950

Website: checkpointtx.com

Address:

95 Sawyer Road, Suite 110, Waltham, United States

Zellchair Sep. 17 at 7:55 PM

$FBIO $FBIOP $CKPT Part 2 (last) ... Additionally, currently approved ICIs are not effective or well tolerated for all patients, highlighting the need for new options that may be fulfilled by cosibelimab-ipdl. FDA approval was based on results from a phase I clinical trial demonstrating that cosibelimab-ipdl helped shrink tumors in nearly half of the patients (620). These responses were also long-lasting, with many patients continuing to benefit for more than a year. These findings, together with the lower rates of reported adverse events compared to other ICIs, suggest that cosibelimab-ipdl could offer a safer and effective new treatment option for patients with advanced CSCC.” https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2025/09/AACR_CPR_2025.pdf

0 · Reply

Zellchair Sep. 17 at 7:55 PM

$FBIO $FBIOP $CKPT Fantastic recognition for UNLOXCYT from the American Association for Cancer Research - Part 1 AACR Cancer Progress Report 2025 “In December 2024, FDA approved cosibelimab-ipdl, a new PD-L1–targeting ICI, for the treatment of adults with advanced cutaneous squamous cell carcinoma (CSCC) that has spread or that is locally advanced and cannot be treated with surgery or radiation intended to cure the disease. CSCC is the second most common form of skin cancer in the United States. While existing PD-1–targeted ICIs have improved outcomes for patients with CSCC, treatment options are still limited for patients with advanced or metastatic disease who cannot undergo curative surgery or radiation. ...

0 · Reply

Zellchair Sep. 17 at 11:12 AM

$FBIO $FBIOP Part 4 And if Helocyte and Triplex don't give you enough certainty about the valuation today, these numbers might do it: Cash in Fortress and its unlisted companies: $38.1M Comment: Fortress has the most of this money after the $CKPT deal, even though it has started paying off the debt to Oaktree. Helocyte is showered with grants for its studies, Urica is no longer conducting any of its own Dotinurad studies, Cyprium is on hold for CUTX-101 PDUFA and further AAV9-ATP7A + CUTX-101 (CUTX-101 2.0) development, while Cellvation and Oncogenuity continue to maintain low activity.

0 · Reply

Zellchair Sep. 17 at 11:09 AM

$FBIO $FBIOP Part 2 There don't seem to be many, based on the share price, who understand that Fortress/Helocyte could do a deal with just one indication that exceeds both the total market cap in FBIO and can secure the dividend in FBIOP for a long time given what already exists with the conditions today with $CKPT sold, Dotinurad under new management (Crystalys) and EMROSI $DERM approved on the market. And yes, the indications are considerably more than one today for Triplex (read next part)...

0 · Reply

Zellchair Sep. 3 at 4:54 PM

$FBIO $FBIOP I also believe this now after Fortress CEO said during the HCW presentation on May 7 that they would repay all loans in 2025, and that in Q2 we saw that the total loan cost to Oaktree decreased from $35.35M in Q1 to $30.369M in Q2. So even though they only had to pay the interest (read substack part 1, I think), they still paid back parts of the loan even though the $CKPT deal closed quite late in Q2. However, I would not rule out that in the event of CUTX-101 approval and PRV sales, perhaps a little illogically, as I have mentioned before, you still wait for the Q3 reporting (even if you do not need TTM of $57.5M then). I think the CEO has hinted for quite some time now that they are looking at new acquisitions and then the Oaktree loan may be worth keeping until the CUTX-101 milestones (note, not royalties) come in.

1 · Reply

Zellchair Sep. 3 at 4:29 PM

$FBIO $FBIOP One thing that I think many Fortress investors don't think about regarding FBIO vs FBIOP is a scenario if CUTX-101, against the odds, is denied or has its FDA approval delayed. I think many think that logically FBIOP should perhaps take as much of a beating as FBIO in such a scenario as one may not be able to discount a long secured dividend in the near future (especially if there is no new announcement for CAEL-101/Anselamimab before then). However, I think that this, a little illogically perhaps, could trigger an earlier reinstated dividend for FBIOP so that Fortress can enable ATM in FBIO if needed. The money from the $CKPT deal should be enough with them out of the balance sheet in Q3 and with a reinstated dividend Fortress also secures some financial aspect.

1 · Reply

Zellchair Aug. 29 at 4:48 PM

$FBIO $FBIOP $CKPT A shorter part (part 10) in my series about the case for the special situation and the fantastic opportunity (in my opinion) I see in Fortress Preferred stock $FBIOP Fortress Biotech Preferred $FBIOP - Checkpoint Therapeutics Q2 - Clarification on reporting in Fortress accounting There will be one longer or several shorter parts next week. Stay tuned. https://zellchair.substack.com/p/fortress-biotech-preferred-fbiop-b87

1 · Reply

Renato17 Aug. 28 at 12:53 PM

$FBIO $FBIOP $DERM $CKPT $MBIO

0 · Reply

Zellchair Aug. 28 at 12:41 PM

$FBIO $FBIOP $DERM $CKPT $MBIO Me (+343,57%) vs FBIO (-2,89%) last 20 months (image), considering that Fortress has been my largest holding several times and for long periods during this time. The curves/development will be more correlated to FBIOP (yes, I continue to prefer the preferred stock) going forward. 9 substack posts about why in link (free) here: https://zellchair.substack.com/

0 · Reply

TREBLALBERT Aug. 25 at 4:16 PM

$CKPT

0 · Reply

Market Cap	370.71M
Revenue (ttm)	40,000.00
Net Income (ttm)	-56.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-140,600.01%
Debt to Equity Ratio	0.00

Volume	8,666,800
Avg Vol	1,808,080
Day's Range	N/A - N/A
Shares Out	87.02M
Stochastic %K	85%
Beta	1.18
Analysts	Sell
Price Target	$4.45